Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Novel Therapy, Toripalimab, Developed to Treat Nasopharyngeal Carcinoma

Toripalimab, a novel therapy has been discovered for the treatment of nasopharyngeal carcinoma by Junshi Biosciences.

Toripalimab, the first anti-PD-1 monoclonal antibody developed for the treatment of Nasopharyngeal carcinoma (NPC) is the first to receive breakthrough designation in China. NPC is one among the most common malignant tumors seen in the people of China. Compared with the world average, the number of people affected with NCP is more in China.

Earlier patients with nasopharyngeal carcinoma would have a good therapeutic effect with 90% can be cured or be tumor-free for a long time lacking specific clinical symptoms.

US Food and Drug Administration (FDA) has granted the Breakthrough Therapy Designation for Toripalimab for the Treatment of Nasopharyngeal Carcinoma.

Nasopharyngeal Carcinoma (NPC) is a malignant tumor which generally occurs in the mucosal epithelium of the nasopharynx, mainly in the parietal and lateral walls of the nasopharynx, particularly in the pharyngeal recess.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024